- Home
- HRMY vs NWBI Comparison
HRMY vs NWBI Comparison
Compare HRMY & NWBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HRMY | NWBI |
|---|---|---|
| Founded | 2017 | 1896 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.1B |
| IPO Year | 2020 | 2009 |
Fundamental Metrics
Financial Performance| Metric | HRMY | NWBI |
|---|---|---|
| Price | $38.12 | $15.75 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $44.11 | $14.50 |
| AVG Volume (30 Days) | 881.8K | ★ 1.1M |
| Earning Date | 05-07-2026 | 04-27-2026 |
| Dividend Yield | N/A | ★ 5.82% |
| EPS Growth | 7.97 | ★ 16.46 |
| EPS | ★ 1.84 | 0.71 |
| Revenue | ★ $868,453,000.00 | N/A |
| Revenue This Year | $19.75 | $6.29 |
| Revenue Next Year | $12.88 | $5.06 |
| P/E Ratio | ★ $20.92 | $22.24 |
| Revenue Growth | ★ 21.51 | N/A |
| 52 Week Low | $25.52 | $11.25 |
| 52 Week High | $40.87 | $16.16 |
Technical Indicators
Market Signals| Indicator | HRMY | NWBI |
|---|---|---|
| Relative Strength Index (RSI) | 56.72 | 59.18 |
| Support Level | $34.87 | $15.07 |
| Resistance Level | $39.24 | $16.16 |
| Average True Range (ATR) | 1.33 | 0.22 |
| MACD | 0.14 | -0.03 |
| Stochastic Oscillator | 66.49 | 53.46 |
Price Performance
Historical ComparisonAbout HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About NWBI Northwest Bancshares Inc.
Northwest Bancshares Inc is a stockholding company for Northwest Bank. Northwest Bank is a stock savings bank and a community-oriented financial institution, offering personal and commercial banking solutions, business services, investment management, trust services, and insurance products. It also offers consumer finance loans through a wholly-owned subsidiary. The bank's loan portfolio segment consists of personal banking and Commercial Banking loans. Personal banking includes residential mortgages, home equity loans, and other consumer loans. Commercial Banking loans consist of commercial real estate loans and commercial loans. Net interest income is the company's primary contributor to revenue.